全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

糖尿病肾病PTH及FT3与显性蛋白尿的相关性
Correlation between PTH, FT3 and Dominant Proteinuria in Diabetic Kidney Disease

DOI: 10.12677/ACM.2021.1112898, PP. 6061-6066

Keywords: 糖尿病肾病,甲状旁腺激素,三碘甲状腺氨酸,蛋白尿
Diabetic Kidney Disease
, Parathyroid Hormone, Triiodothyronine, Albuminuria

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:糖尿病及糖尿病肾病发病率日益提升,糖尿病肾病为终末期肾病的重要发病因素,且糖尿病肾病首先表现为尿白蛋白排泄增加。本文研究PTH及FT3与显性蛋白尿的关系。方法:选择2019~2020于青岛大学附属医院住院治疗的糖尿病肾病患者,共514位,根据尿蛋白排泄分为微量蛋白尿组(随机UACR 30~300 mg/g),共322位患者;显性蛋白尿组(随机UACR > 300 mg/g),共192位。应用Logistic回归分析PTH及FT3与显性蛋白尿的关系。结果:二元Logistic回归提示PTH及FT3为显性蛋白尿的危险因素,PTH (OR = 1.012,p = 0.002)、FT3 (OR = 0.718,p = 0.017)。结论:PTH及FT3为显性蛋白尿的危险因素,PTH升高及FT3降低对蛋白尿增加具有早期提示意义。
Objective: The incidence of diabetes and diabetic kidney disease is increasing day by day. Diabetic kidney disease is an important factor in the pathogenesis of end-stage renal disease, and diabetic kidney disease is first manifested as increased urinary albumin excretion. This article studies the relationship between PTH, FT3 and dominant proteinuria. Methods: A total of 514 patients with diabetic kidney disease who were hospitalized in the Affiliated Hospital of Qingdao University from 2019 to 2020 were selected and divided into the microalbuminuria group (random UACR 30~300 mg/g) according to urine protein excretion, a total of 322 patients; dominant proteinuria group (Random UACR > 300 mg/g), 192 digits in total. Logistic regression was used to analyze the relationship between PTH, FT3 and dominant proteinuria. Results: Binary Logistic regression indicated that PTH and FT3 were risk factors for dominant proteinuria, PTH (OR = 1.012, p = 0.002), FT3 (OR = 0.718, p = 0.017). Conclusion: PTH and free T3 are the risk factors for dominant proteinuria. The increase of PTH and the decrease of free T3 have early prompting significance for the increase of proteinuria.

References

[1]  Koye, D., Magliano, D., Nelson, R., et al. (2018) The Global Epidemiology of Diabetes and Kidney Disease. Advances in Chronic Kidney Disease, 25, 121-132.
https://doi.org/10.1053/j.ackd.2017.10.011
[2]  American Diabetes Association (2020) Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020. Diabetes Care, 43, S135-S151.
[3]  Cheng, H., Xu, X., Lim, P., et al. (2021) Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015. Diabetes Care, 44, 89-97.
https://doi.org/10.2337/dc20-1913
[4]  中国2型糖尿病防治指南(2020年版) (下) [J]. 中国实用内科杂志, 2021, 41(9): 757-784.
[5]  Mogensen, C., Christensen, C. and Vittinghus, E. (1983) The Stages in Diabetic Renal Disease. With Emphasis on the Stage of Incipient Diabetic Nephropathy. Diabetes, 32, 64-78.
https://doi.org/10.2337/diab.32.2.S64
[6]  Oshima, M., Shimizu, M., Yamanouchi, M., et al. (2021) Trajectories of Kidney Function in Diabetes: A Clinicopathological Update. Nature Reviews Nephrology, 17, 740-750.
https://doi.org/10.1038/s41581-021-00462-y
[7]  Ketteler, M. and Ambühl, P. (2021) Where Are We Now? Emerging Opportunities and Challenges in the Management of Secondary Hyperparathyroidism in Patients with Non-Dialysis Chronic Kidney Disease. Journal of Nephrology, 34, 1405-1418.
https://doi.org/10.1007/s40620-021-01082-2
[8]  Bargagli, M., Arena, M., Naticchia, A., et al. (2021) The Role of Diet in Bone and Mineral Metabolism and Secondary Hyperparathyroidism. Nutrients, 13, 2328.
https://doi.org/10.3390/nu13072328
[9]  González, E., Sachdeva, A., Oliver, D., et al. (2004) Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease. A Single Center Observational Study. American Journal of Nephrology, 24, 503-510.
https://doi.org/10.1159/000081023
[10]  Kuro, O. (2012) Klotho in Health and Disease. Current Opinion in Nephrology and Hypertension, 21, 362-368.
https://doi.org/10.1097/MNH.0b013e32835422ad
[11]  Choi, B., Kim, C., Lim, Y., et al. (2010) Transcriptional Activation of the Human Klotho Gene by Epidermal Growth Factor in HEK293 Cells; Role of Egr-1. Gene, 450, 121-127.
https://doi.org/10.1016/j.gene.2009.11.004
[12]  Cunningham, J., Locatelli, F. and Rodriguez, M. (2011) Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options. Journal of the American Society of Nephrology, 6, 913-921.
https://doi.org/10.2215/CJN.06040710
[13]  Da Costa, A., Pellizzari, C., Carvalho, G., et al. (2016) High Prevalence of Subclinical Hypothyroidism and Nodular Thyroid Disease in Patients on Hemodialysis. Hemodialysis International, 20, 31-37.
https://doi.org/10.1111/hdi.12339
[14]  Kaptein, E. (1996) Thyroid Hormone Metabolism and Thyroid Diseases in Chronic Renal Failure. Endocrine Reviews, 17, 45-63.
https://doi.org/10.1210/edrv-17-1-45
[15]  Sanai, T., Okamura, K., Kishi, T., et al. (2015) Importance of Specific Reference Values for Evaluation of the Deteriorating Thyroid Function in Patients with End-Stage Renal Disease on Hemodialysis. Journal of Endocrinological Investigation, 38, 47-56.
https://doi.org/10.1007/s40618-014-0121-6
[16]  Zhao, W., Li, X., Liu, X., et al. (2018) Thyroid Function in Patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy: A Single Center Study. Journal of Thyroid Research, 2018, Article ID: 9507028.
https://doi.org/10.1155/2018/9507028
[17]  Fei, X., Xing, M., Wo, M., et al. (2018) Thyroid Stimulating Hormone and Free Triiodothyronine Are Valuable Predictors for Diabetic Nephropathy in Patient with Type 2 Diabetes Mellitus. Annals of Translational Medicine, 6, 305.
https://doi.org/10.21037/atm.2018.07.07

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133